NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis

Similar documents
IMPACT OF IMPROVED TREATMENT SUCCESS ON THE PREVALENCE OF TB IN A RURAL COMMUNITY BASED ON ACTIVE SURVEILLANCE

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)

Management of Tuberculosis Training for Health Facility Staff. F: Manage Drugs and Supplies for TB. WORLD HEALTH ORGANIZATION Geneva

Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor

Revised National Tuberculosis Control Programme

Original Article. Karanjekar VD, Lokare PO 1, Gaikwad AV 2, Doibale MK 3, Gujrathi VV 2, Kulkarni AP 4. Abstract. Introduction

Authors Malhotra, S; Zodpey, S P; Chandra, S; Vashist, R P; Satyanaryana, S; Zachariah, R; Harries, A D

Ramesh P. M.*, Saravanan M.

Management of Tuberculosis Training for Health Facility Staff. C: Treat TB Patients. WORLD HEALTH ORGANIZATION Geneva

11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction

Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.

National TB Program (NTP)

HIV Clinicians Society Conference TB/HIV Treatment Cascade

Managing the Revised National Tuberculosis Control Programme in Your Area. A Training Course. Modules 1 4

Revised National Tuberculosis Control Programme

Management of Tuberculosis Training for Health Facility Staff

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Management of Tuberculosis Training for Health Facility Staff. J: Reference Booklet. WORLD HEALTH ORGANIZATION Geneva

Let s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

A 50-year-old male with fever, cough, dyspnoea, chest pain, weight loss and night sweats

Index No. All five (05) questions should be answered. All questions carry equal marks.

Assessing the programmatic management of drug-resistant TB

STATUS OF RE-REGISTERED PATIENTS FOR TUBERCULOSIS TREATMENT UNDER DOTS PROGRAMME

Pediatric tuberculosis (i.e., Tuberculosis

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Multi-drug Resistant Tuberculosis in Rajshahi District

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru

Chemotherapy of tuberculosis in Hong Kong: a consensus statement

Definitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013

Treatment Outcome of Pulmonary and Extra Pulmonary Tuberculosis Patients in TB and Chest Disease Hospital DOT Centre, Goa, India

Osaka City is the third largest city (population

HA Convention 2016 : Special Topic Session 3 May 2016

CHAPTER 2. Literature review

Northwestern Polytechnic University

ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM

TB: A Supplement to GP CLINICS

Performance of RNTCP NTI Bulletin 2005,41/3&4,

Role of RNTCP in the management MDR-TB

TUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION In the WHO Western Pacific Region 2002 Report

Ministry of Health. National Tuberculosis Control Program INTEGRATED TB HIV PROGRAM REPORT (JANUARY JUNE 2015)

Basic Overview of Tuberculosis Epidemiology in the Czech Republic in 2017

COMMONEST CAUSE OF INITIATING CATEGORY II DIRECTLY OBSERVED TREATMENT SHORT COURSE IN TUBERCULOSIS PATIENTS

Response to Treatment in Sputum Smear Positive Pulmonary Tuberculosis Patients In relation to Human Immunodeficiency Virus in Kano, Nigeria.

RISK FACTORS FOR POOR TUBERCULOSIS TREATMENT OUTCOMES IN MAKASSAR, INDONESIA

Principles and Structure of a Research Protocol. Anthony D Harries The Union, Paris, France MSF, Brussels, Belgium

Predicting outcomes and drug resistance with standardised treatment of active tuberculosis

Overview of the Presentation

SA TB Guidelines The interface with Advanced Clinical Care

TB the basics. (Dr) Margaret (DHA) and John (INZ)

Vidarbha Journal of Internal Medicine Volume 22 January 2017

DR-TB Patient Treatment Log Book

DG MEMORANDUM FOR TUBERCULOSIS

Research Article Five-Year Assessment of Time of Sputum Smears Conversion and Outcome and Risk Factors of Tuberculosis Patients in Central Iran

Management of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

South West. Tuberculosis Treatment Outcome Surveillance for the South West

Update on Management of

Symptoms Latent TB Active TB

Diagnosis and Treatment of Tuberculosis, 2011

The New England Journal of Medicine. Special Article CONTROLLING TUBERCULOSIS IN INDIA

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Research Article Characteristics and Treatment Outcomes of Retreatment Tuberculosis Patients in Benin

Tuberculosis (2005) Department of Health

A review of compliance to anti tuberculosis treatment and risk factors for defaulting treatment in Sub Saharan Africa

Health Examination Guidelines For Entry Into Universiti Tunku Abdul Rahman

SMEAR MICROSCOPY AS SURROGATE FOR CULTURE DURING FOLLOW UP OF PULMONARY MDR-TB PATIENTS ON DOTS PLUS TREATMENT

Basic Overview of Tuberculosis Epidemiology in the Czech Republic in 2015

Outcome of Tuberculosis Treatment in Tertiary Hospital in South Eastern Nigeria

TOG The Way Forward

UC DavisTB Screening Requirement: How to submit your TB Health Assessment Form

Therapeutic TB vaccines Shortening Treatment for (DS- and) DR-TB?

Keywords: Tuberculosis; Pulmonary and Extra-Pulmonary Forms; Therapeutic Evaluation; Rural Area; West Algeria

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

1 Appendix D: Evidence Tables Treatment of active TB (RQs I, K, L, M, & P)

Annual Epidemiological Report

MRIMS Journal of Health Sciences 2016;4(3) pissn: , eissn:

Research Article Photovoice: A Novel Approach to Improving Antituberculosis Treatment Adherence in Pune, India

Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis

Open Access Article pissn eissn

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.

M ultidrug resistant (MDR) tuberculosis (TB) has

M.A. SEETHA, G.E. RUPERT SAMUEL and V.B. NAIDU (From National TB Institute, Bangalore)

STATUS OF TUBERCULOSIS CONTROL IN THAILAND*

TB & HIV. GOVERNMENT OF INDIA NATIONAL TUBERCULOSIS INSTITUTE No.8, Bellary Road, Bangalore INDIA

Virtual Implementation Evaluation of Tuberculosis diagnostics in Tanzania Ivor Langley, Liverpool School of Tropical Medicine

Tuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012

Application for addition of 3-FDC rifampicin 150/isoniazid 75/ethambutol 275 mg (RHE) to the WHO model list of essential medicines

Information Note. WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis

Population, Health and Nutrition Department World Bank

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Table S1: Summary of randomized trials pooled for analysis of isoniazid resistance

The emerging threat of multidrug resistant TB: Global and local challenges and solutions

Determinants of sputum conversion at two months of treatment under National Tuberculosis Programme, South India

Characteristics and Programme-Defined Treatment Outcomes among Childhood Tuberculosis (TB) Patients under the National TB Programme in Delhi

SEA/TB/233 Distribution:General. Tuberculosis Control An Annotated Bibliography

Prevalence and predictors of default from tuberculosis treatment in Hong Kong

MEMORANDUM. Re: Guidance for follow-up of newly-arrived individual with Class B1 Tuberculosis Pulmonary Tuberculosis, no treatment

Treatment of Tuberculosis, 2017

TUBERCULOSIS TREATMENT WITH MOBILE-PHONE MEDICATION REMINDERS IN NORTHERN THAILAND

Transcription:

NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis Patients registered during quarter* of 20 Name of area No.# Name of the Reporter Signature: Date of Completion of this form Block 1: All patients registered in the quarter d d m m Pulmonary tuberculosis Extra-pulmonary Smear-positive Total Smear-negative tuberculosis New Cases Relapse (5) (3) (4) (1) (2) M F Total M F M F M F M F Total 2 0 Block 2: Smear-positive new cases only: from Column(1) above Age-group (years) Total 0-14 15-24 25-34 35-44 45-54 55-64 65 and above M F M F M F M F M F M F M F M F Total Block 3: Treatment Regimen given Regimen A a Regimen B b Regimen 1 c Regimen 2 d Total Type of patient Smear- Others (Smear-positive Smear- Others Smear- Others positive patients only) positive positive New Relapse Failure Return after default Others Total Notes: * Quarters: 1 st quarter January,Febrauary,March 2 nd quarter April, May, June 3 rd quarter July, August, September. 4 th quarter October,November, December #Number Identification number of the area a Regimen A [2HRZE 6HE OR 2HRZE 6HT] b Regimen B [2HRZS 4(HRS) 2 every dose supervised] c Regimen 1 [2HSE 10HE or 2HST 10HT] d Regimen 2 [12 HE or 12 HT

How to fill in the form Block 1: New cases and relapses of tuberculosis registered during quarter of (year) (Fill in the quarter and year) Column (1): Smear- positive new cases Column (2): Smear-positive relapses Column (3): Smear-negative Cases Column (4): Extra-pulmonary tuberculosis Patients with sputum smear-positive pulmonary tuberculosis who have never received anti- Tuberculosis treatment or have received treatment for less than 4 weeks. Patients with sputum smear-positive pulmonary tuberculosis who were declared cured by a Medical Officer but have now got the disease again. Patients with pulmonary tuberculosis with 3 sputum samples negative for AFB, in whom the diagnosis of tuberculosis was made by means other than sputum microscopy. Patients with tuberculosis of organs other than the lungs. Column (5): Total Males Add all male patients in columns 1+2+3+4 Females Add all female patients in columns 1+2+3+4 Total Add all patients (males +females) in columns 1+2+3+4 Block 2: Smear-positive new cases: from Column (1) above. In this block enter the patients already recorded in Block 1, Column (1) according to their sex and age group. If the exact age of a patient is not known at the time of his/her registration it should be estimated to the nearest 5 years (e.g. 15,20,25, etc). Block 3 : This gives category-wise break up of treatment regimens for new patients (both smear-positive and smear- negative), relapses, failures, return to treatment after default (RAD), and patients who are classified as others.

NATIONAL TUBERCULOSIS CONTROL PROGRAMME SCC AREA Quarterly Report of Sputum Conversion of New Cases Patients registered during Quarter of 20 Name of area: No Name of reporter: Signature: Date of completion of this form: d d m m 2 0 0 Complete this proforma for sputum smear-positive patients. The total number should be the same as in Block-3 of the Quarterly Report on New and Retreatment Cases of Tuberculosis of the previous quarter. Total number of Sputum smear positive patients treated with Regimen A [2 HRZE 6HE] Sputum at 2 months Negative Positive NA Total number of Sputum smear positive patients treated with Regimen B [2 HRZS 4(HRS) 2 ] Sputum at 2 months Negative Positive NA N.A. - Not available; sputum examination was not done.

NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on the Results of Treatment of Smear Positive Patients Registered 12-15 Months Earlier Name of district: No.: Date of completion of this form 200 Patients registered during Quarter of 200 Name of Reporter*: Signature: Patients reported during quarter** Type of patient (all smearpositive patients put on treatment) Pulmonary smear-positive cases treated with Regimen A [2HRZE 6 HE or 2HRZE 6HT] Other Cases treated with Regimen A [2HRZE 6HE or 2HRZE 6HT] Cases treated with Regimen B [2HRZS 4 (HRS) 2 ] Cured Treatment completed Died Failure Defaulted Transferred to another district Total number evaluated (sum of columns 1 to 6) (1) (2) (3) (4) (5) (6) (7) *The Reporter is the Medical Officer responsible, not the person completing this form. This form includes all smear-positive patients. These totals should match those of the Quarterly Report on New and Retreatment cases for the quarter. * Of these, (number) were excluded from evaluation of chemotherapy for the following reasons:

NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on Programme Management and Logistics Name of the District Quarter: Year: Microscopy Activities Number of chest symptomatic patients whose sputum was examined for case-finding (diagnosis) Number of Smear positive patients diagnosed Staff Position and Training ( Check if in place or not during quarter) District Tuberculosis Officer in place Yes No Trained in revised Yes No Medical Officer of the DTC Yes (No. ) No Trained in revised Yes No Statistical Assistance in place Yes No Trained in revised Yes No Treatment Organizer in place Yes No Trained in revised Yes No District Tuberculosis Officer in place Yes No Trained in revised Yes No Equipment in Place Item Number In working condition Not in working condition Monocular microscopes Binocular microscopes X-ray machine Photocopier Overhead projector Jeep Two/three-wheeler

Medication Item Daily Combipack for intensive phase treatment with (HRZE) Stock on first day of quarter Stock received during the quarter Consumption during quarter Stock on last day of quarter 1 2 3 4 Isoniazid 300 mg Isoniazid 100 mg Isoniazid 75 mg/ Thiacetazone 37.5 mg Isoniazid 150 mg/ Thiacetazone 75mg Isoniazid 300 mg/ Thiacetazone 150mg Rifampicin 450 mg Rifampicin 300 mg Rifampicin 150 mg Pyrazinamide 500 mg Ethambutol 800 mg Ethambutol 400 mg Ethambutol 200 mg Streptomycin 1000 mg Streptomycin 750 mg Name of the Officer reporting (in Capital Letters): Signature : Date: